AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.